NCT01215279 - AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

March 31, 2011

Conditions

Chronic Obstructive Pulmonary DiseaseLung Disease

Interventions

DRUG

AZD2423

100 mg oral treatment once daily for 28 days

DRUG

Placebo to AZD2423

Oral treatment once daily for 28 days

Trial Locations (6)

Research Site, Rousse

Research Site, Sofia

Research Site, Bratislava

Research Site, Košice

Research Site, Prešov

Research Site, Žilina